- PA5-19474 - Invitrogen Antibodies PADI2 antibody

Submitted references Activation of Peptidylarginine Deiminase in the Salivary Glands of Balb/c Mice Drives the Citrullination of Ro and La Ribonucleoproteins.

Rodríguez-Rodríguez M, Herrera-Esparza R, Bollain Y Goytia JJ, Pérez-Pérez ME, Pacheco-Tovar D, Murillo-Vázquez J, Pacheco-Tovar G, Avalos-Díaz E
Journal of immunology research 2017;2017:8959687

Potential protein targets of the peptidylarginine deiminase 2 and peptidylarginine deiminase 4 enzymes in rheumatoid synovial tissue and its possible meaning.

Badillo-Soto MA, Rodríguez-Rodríguez M, Pérez-Pérez ME, Daza-Benitez L, Bollain-Y-Goytia JJ, Carrillo-Jiménez MA, Avalos-Díaz E, Herrera-Esparza R
European journal of rheumatology 2016 Jun;3(2):44-49

Posttranslational Protein Modification in the Salivary Glands of Sjögren's Syndrome Patients.

Herrera-Esparza R, Rodríguez-Rodríguez M, Pérez-Pérez ME, Badillo-Soto MA, Torres-Del-Muro F, Bollain-Y-Goytia JJ, Pacheco-Tovar D, Avalos-Díaz E
Autoimmune diseases 2013;2013:548064

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of Human Kidney Lysate using Product # PA5-19474, PADI2/PAD2 primary antibody at a dilution of 1 µg/mL.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent staining of HEK293 cells using Product # PA5-19474, anti-PADI2/PAD2 antibody. The cells were fixed with PFA (4%)for 10 minutes, permabilised PBS-T for 20 minutes and exposed to the primary antibody at a concentration of 5 µg/mL for 1 hour at room temp. A solution of BSA (1%), normal goat serum (10%) and glycine (0.3 M) was used to quench autofluorescence and block non-specific protein-protein interactions. The secondary antibody was a 448 fluorescence conjugated Goat anti-rabbit IgG (green) at a dilution of 1:1000. A WGA- 594 fluorescent conjugated stain was used to label plasma membranes (red) and the nuclei stain was DAPI (blue).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent staining of HEK293 cells using Product # PA5-19474, anti-PADI2/PAD2 antibody. The cells were fixed with PFA (4%)for 10 minutes, permabilised PBS-T for 20 minutes and exposed to the primary antibody at a concentration of 5 µg/mL for 1 hour at room temp. A solution of BSA (1%), normal goat serum (10%) and glycine (0.3 M) was used to quench autofluorescence and block non-specific protein-protein interactions. The secondary antibody was a 448 fluorescence conjugated Goat anti-rabbit IgG (green) at a dilution of 1:1000. A WGA- 594 fluorescent conjugated stain was used to label plasma membranes (red) and the nuclei stain was DAPI (blue).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of PADI2 was performed using 70% confluent log phase A-549 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 2% BSA for 1 hour at room temperature. The cells were labeled with PADI2 Polyclonal Antibody (Product # PA5-19474) at 1:100 dilution in 0.1% BSA and incubated overnight at 4 degree and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Recombinant Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the composite image showing nuclear localization. Panel e represents control cells with no primary antibody to assess background. The images were captured at 60X magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Knockdown of PADI2 was achieved by transfecting A-549 cells with PADI2 specific siRNA (Silencer® select Product # s22188, Product # s22187). Immunofluorescence analysis was performed on A549 cells (untransfected, panel a,d), transfected with non-specific scrambled siRNA (panels b,e) and transfected with PADI2 specific siRNA (panel c,f). Cells were fixed, permeabilized, and labelled with PADI2 Polyclonal Antibody (Product # PA5-19474, 1:100 dilution), followed by Goat anti-Rabbit IgG (H+L) Superclonal™ Recombinant Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A27034, 1:2000). Nuclei (blue) were stained using ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962), and Rhodamine Phalloidin (Product # R415, 1:300) was used for cytoskeletal F-actin (red) staining. Reduction of specific signal was observed upon siRNA mediated knockdown (panel c,f) confirming specificity of the antibody to PADI2 (green). The images were captured at 60X magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Immunohistochemistry of minor salivary glands from Sjogren patients; the superior panel shows an overview of immunoreagent distribution at 10x magnification; the inferior panel showed a close up at 40x magnification. (A) and (E). Incubated with PBS. (B) and (F). Treated with anti-CCP. (C) and (G). Anti-PAD2. (D) and (H). Anticitrulline. Note the correlation between CCP, PAD2, and citrulline expression in a duct.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Immunohistochemistry of minor salivary glands. The superior panel corresponds to normal controls, and the inferior panel belongs to one representative biopsy of a Sjogren patient. (A) and (E). Incubated with PBS. (B) and (F). Treated with anti-CCP. (C) and (G). Anti-PAD2. (D) and (H). Anticitrulline. Observe the immunoreagents positivity at ducts and acini in (F), (G), and (H).

PA5-19474

Antibody data